Folate-Engineered Microvesicles for Enhanced Target and Synergistic Therapy toward Breast Cancer
Source abstract
Abstract
As an ideal nanovector candidate, microvesicles (MVs) have been gradually utilized for packaging kinds of functional molecules for effective tumor diagnosis and therapy; however, the deficiency of their tumor targeting influenced their therapy efficacy. Through a facile phospholipid substitution strategy, MVs-based drug delivery system (DDS) was apparently endowed with high tumor targeting toward breast cancer thanks to the modified folate onto the membrane of MVs, simultaneously possessing a synergistic antitumor effect, and in vivo tumor imaging attributed to the SA-QDs labeling. Tumor killing effect could be improved up to 15 percentages with the help of the improved tumor targeting ability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Chemistry and Molecular Sciences, Key Laboratory of Analytical Chemistry for Biology and Medicine (Ministry of Education), Wuhan University, Wuhan 430072, China
School and Hospital of Stomatology, Key Laboratory of Oral Biomedicine (Ministry of Education) and Department of Oral and Maxillofacial Surgery, Wuhan University, Wuhan 430079, China
Funding
Natural Science Foundation of Hubei Province · National Natural Science Foundation of China
References (40)
Show source-provided references
1. 10.1021/ja404985w10.1021/ja404985w ↗
2. 10.1021/acsnano.5b0306010.1021/acsnano.5b03060 ↗
3. 10.1002/adma.20160219310.1002/adma.201602193 ↗
4. 10.1002/anie.20151040910.1002/anie.201510409 ↗
5. 10.1021/cm503647k10.1021/cm503647k ↗
6. 10.1002/adma.20070197510.1002/adma.200701975 ↗
7. 10.1038/nnano.2007.10810.1038/nnano.2007.108 ↗
8. 10.1021/nn800551s10.1021/nn800551s ↗
9. 10.1016/j.biomaterials.2010.07.05810.1016/j.biomaterials.2010.07.058 ↗
10. 10.1002/adma.20150623210.1002/adma.201506232 ↗
11. 10.1002/adma.20150582210.1002/adma.201505822 ↗
12. 10.1016/j.addr.2015.04.00810.1016/j.addr.2015.04.008 ↗
13. 10.1002/smll.20140209210.1002/smll.201402092 ↗
14. 10.1021/nn504905q10.1021/nn504905q ↗
15. 10.1021/acs.chemmater.6b0126710.1021/acs.chemmater.6b01267 ↗
16. 10.1021/jacs.5b0997410.1021/jacs.5b09974 ↗
17. 10.1039/C5CS00569H10.1039/C5CS00569H ↗
18. 10.1039/C5CS00798D10.1039/C5CS00798D ↗
19. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
20. 10.1126/science.221849410.1126/science.2218494 ↗
21. 10.1038/ncomms228210.1038/ncomms2282 ↗
22. 10.1016/j.molmed.2014.03.00210.1016/j.molmed.2014.03.002 ↗
23. 10.1021/cb200187810.1021/cb2001878 ↗
24. 10.1002/anie.20141022310.1002/anie.201410223 ↗
25. 10.1021/jacs.5b1034010.1021/jacs.5b10340 ↗
26. 10.1038/nrc240310.1038/nrc2403 ↗
27. 10.1016/S0304-3835(97)00326-110.1016/S0304-3835(97)00326-1 ↗
28. 10.1158/1538-7445.AM2016-382110.1158/1538-7445.AM2016-3821 ↗
29. 10.1083/jcb.20121113810.1083/jcb.201211138 ↗
30. 10.1016/j.cell.2016.01.04310.1016/j.cell.2016.01.043 ↗
31. 10.1021/nl203021310.1021/nl2030213 ↗
32. 10.1039/c2cs15309b10.1039/c2cs15309b ↗
33. Neumann E. · EMBO. J. · 1982 · 1 · 84110.1002/j.1460-2075.1982.tb01257.x ↗
34. 10.1093/nar/16.13.612710.1093/nar/16.13.6127 ↗
35. 10.1038/nmat173710.1038/nmat1737 ↗
36. 10.1002/adhm.20120033810.1002/adhm.201200338 ↗
37. 10.1016/j.jconrel.2005.02.00610.1016/j.jconrel.2005.02.006 ↗
38. 10.1038/nnano.2009.33310.1038/nnano.2009.333 ↗
39. Gregory R. E. · Clin. Pharmacol. · 1993 · 12 · 401
40. Seidman A. D. · Clin. Cancer. Res. · 1995 · 1 · 247